文献速递甲状腺疾病

一项回顾性病例对照研究:促甲状腺激素抑制与[18F]FDG-PET/CT所示血管壁炎症的关联

A Retrospective Case-Control Study Examining the Association of Thyroid-Stimulating Hormone Suppression and Vascular Wall Inflammation on [18F]FDG-PET/CT.
PubMed 文献 · Thyroid · 2025-03-07

该回顾性病例对照研究纳入40例分化型甲状腺癌术后接受促甲状腺激素(TSH)抑制治疗的患者,以25例甲状腺功能正常者为对照,采用[18F]FDG-PET/CT测量动脉壁摄取。TSH抑制组在升主动脉、主动脉弓、腹主动脉、颈动脉及所有动脉合并的靶本底比最大值(TBRmax)均显著高于对照组(p<0.001)。24例持续TSH抑制治疗的患者在平均1.9±1.1年后随访扫描,五个动脉部位的[18F]FDG摄取均无显著变化(p>0.05)。

要点

  • TSH抑制组升主动脉、主动脉弓、腹主动脉、颈动脉及所有动脉合并的TBRmax均显著高于甲状腺功能正常对照组(p<0.001)。
  • 持续TSH抑制治疗平均1.9±1.1年后,五个动脉部位的[18F]FDG摄取较基线均无显著变化(p>0.05)。
  • 作者认为TSH抑制患者血管[18F]FDG摄取增加,可能提示心血管疾病风险更高。

核心结论

  • 本研究提示,接受TSH抑制治疗的患者血管[18F]FDG摄取(动脉炎症标志物)可能显著增加,因此可能面临更高的心血管疾病风险。
  • 在本研究中,TSH抑制持续时间与血管[18F]FDG摄取无显著关联,提示观察到的动脉炎症增加可能不受TSH抑制持续时间的影响。

研究设计与样本

  • 回顾性病例对照研究,纳入40例分化型甲状腺癌术后接受TSH抑制治疗并接受[18F]FDG-PET/CT的患者,以25例甲状腺功能正常者为对照组。
  • 另分析24例持续TSH抑制治疗患者的随访PET/CT以评估长期变化。
  • 在颈动脉、主动脉弓以及升主动脉、降主动脉和腹主动脉测量[18F]FDG摄取,所有测量值按体重归一化并以腔静脉血池活性校正,生成靶本底比(TBR)。

主要发现

  • TSH抑制组升主动脉、主动脉弓、腹主动脉、颈动脉及所有动脉合并的TBRmax(均值±标准差)分别为1.8±0.4、1.8±0.3、1.9±0.4、1.4±0.3、1.7±0.2,均显著高于甲状腺功能正常对照组的1.4±0.2、1.4±0.2、1.4±0.2、1.1±0.2、1.3±0.1(p<0.001)。
  • 在平均持续TSH抑制治疗1.9±1.1年后接受额外随访扫描的亚组中,两次扫描间五个动脉部位的[18F]FDG摄取均无显著变化(p>0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: This retrospective case-control study aimed to investigate the effects of thyroid-stimulating hormone (TSH) suppression on vascular wall inflammation, assessed by [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). Vascular [18F]FDG-uptake is highly correlated with arterial inflammation, which represents a major risk factor for atherosclerotic plaques. Methods: Forty patients with differentiated thyroid cancer underwent [18F]FDG-PET/CTs under TSH suppression therapy following surgical removal of the thyroid and subsequent radioiodine ablation. The [18F]FDG-uptake was measured in the carotid arteries, aortic arch, and the ascending, descending, and abdominal aorta. All measurements in the PET scans were normalized to body weight and corrected for blood pool activity in the superior vena cava, creating target-to-background ratios (TBRs). Twenty-five patients with euthyroid hormone status were used as a control group. In addition, to evaluate long-term changes, the follow-up PET/CTs of 24 thyroid carcinoma patients under continued TSH suppression therapy were analyzed. Results: In patients with TSH suppression, significantly higher arterial [18F]FDG-uptake (p < 0.001) was observed in the ascending aorta, aortic arch, abdominal aorta, carotid artery, and for all arterial vessels combined (mean TBRmax ± standard deviation [SD]: 1.8 ± 0.4, 1.8 ± 0.3, 1.9 ± 0.4, 1.4 ± 0.3, 1.7 ± 0.2, respectively) compared with the euthyroid control group (TBRmax ± SD: 1.4 ± 0.2, 1.4 ± 0.2, 1.4 ± 0.2, 1.1 ± 0.2, 1.3 ± 0.1, respectively). In the subgroup of patients who received an additional follow-up scan after a mean duration of 1.9 ± 1.1 years of continued TSH suppression therapy, no significant changes in arterial [18F]FDG-uptake were found in the five arterial sites when both scans were compared over time (p > 0.05). Conclusions: Our study suggests that patients under TSH suppression may experience a significant increase in vascular [18F]FDG-uptake, a marker of arterial inflammation, and, therefore, might be at higher risk for cardiovascular disease. Interestingly, the duration of TSH suppression was not significantly associated with vascular [18F]FDG-uptake in our study, indicating that the observed increase in arterial inflammation may not be influenced by the duration of TSH suppression.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Einspieler H, Hennig B, Reiterits B, et al. A Retrospective Case-Control Study Examining the Association of Thyroid-Stimulating Hormone Suppression and Vascular Wall Inflammation on [18F]FDG-PET/CT. Thyroid. 2025. PMID: 40053389. doi:10.1089/thy.2024.0476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。